A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Completed · Phase 3 · NCT04039607
Conditions: Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $162,967
- U.S. investigators named
- 9
- Sites paid
- 5
- Planned or actual enrollment
- 732
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (drug), Ipilimumab (drug), Sorafenib (drug), lenvatinib (drug)
- Dates
- Started 2019-09-30; completion 2026-07-09
- Results posted
- Not yet
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
From ClinicalTrials.gov, last updated 2026-08-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $162,967 in research payments for this study in 2025 (7 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Armonde A. Baghdanian, M.D. Radiology · Los Angeles, CA
- Stephan W. Anderson, M.D. Radiology · Boston, MA
- Gregg A. Miller, M.D. Radiology · Boston, MA
- Rendon C. Nelson, M.D. Radiology · Durham, NC
- Aiwu R. He, MD, PHD Medical Oncology · New York, NY
- Marcus S. Noel, MD Medical Oncology · Rochester, NY
- Mirelis Acosta, M.D. Hematology & Oncology · San Juan, PR
- James Schuster JR., M.D. Radiology · Fredericksburg, VA
- Petar Duvnjak, M.D. Radiology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gi Reviewers $102,888
- Radmd, Llc $25,400
- Georgetown University $16,458
- $15,405
- Fdi Clinical Research $2,514
- Georgetown University School of Medicine $302
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.